139 related articles for article (PubMed ID: 7738389)
21. Contact allergy as a therapeutic tool for alopecia areata: application of squaric acid dibutylester.
Happle R; Kalveram KJ; Büchner U; Echternacht-Happle K; Göggelmann W; Summer KH
Dermatologica; 1980; 161(5):289-97. PubMed ID: 7439477
[TBL] [Abstract][Full Text] [Related]
22. Clinical experience on the treatment of alopecia areata with squaric acid dibutyl ester.
Giannetti A; Orecchia G
Dermatologica; 1983; 167(5):280-2. PubMed ID: 6653853
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for resistant and/or severe alopecia areata in a university hospital setting in Northern Mexico.
Herz-Ruelas ME; Lozano-Peña AK; Ocampo-Candiani J; Gómez-Flores M; Welsh-Lozano O; Vázquez-Martínez O
Australas J Dermatol; 2020 Feb; 61(1):e137-e139. PubMed ID: 31385296
[No Abstract] [Full Text] [Related]
24. Persistent allergic contact dermatitis at the site of primary sensitization with squaric acid dibutyl ester.
Nasca MR; Cicero RL; Innocenzi D; Micali G
Contact Dermatitis; 1995 Dec; 33(6):438. PubMed ID: 8706413
[No Abstract] [Full Text] [Related]
25. Alopecia areata. Pathogenesis and topical immunotherapy.
Perret CM; Steijlen PM; Happle R
Int J Dermatol; 1990 Mar; 29(2):83-8. PubMed ID: 2182554
[No Abstract] [Full Text] [Related]
26. Treatment of alopecia areata with squaric acid dibutylester.
Micali G; Cicero RL; Nasca MR; Sapuppo A
Int J Dermatol; 1996 Jan; 35(1):52-6. PubMed ID: 8838932
[TBL] [Abstract][Full Text] [Related]
27. Topical immunotherapy with squaric acid dibutylester: unusual hair pigmentary changes in two cases of alopecia areata.
Mastrolonardo M; Diaferio A
J Eur Acad Dermatol Venereol; 2002 Mar; 16(2):186. PubMed ID: 12046838
[No Abstract] [Full Text] [Related]
28. Treatment of severe alopecia areata with squaric acid dibutylester in pediatric patients.
Orecchia G; Malagoli P; Santagostino L
Pediatr Dermatol; 1994 Mar; 11(1):65-8. PubMed ID: 8170854
[TBL] [Abstract][Full Text] [Related]
29. Effective squaric acid dibutylester immunotherapy is associated with a reduction of skin infiltrating T-helper (Th)1 and Th17 cells in alopecia areata patients.
Avitabile S; Sordi D; Garcovich S; Colonna L; De Luca A; Nasorri F; Mazzanti C; Cavani A
J Dermatol; 2015 Jan; 42(1):98-9. PubMed ID: 25495487
[No Abstract] [Full Text] [Related]
30. Contact immunotherapy-induced Renbök phenomenon in a patient with alopecia areata and psoriasis vulgaris.
Ito T; Hashizume H; Takigawa M
Eur J Dermatol; 2010; 20(1):126-7. PubMed ID: 19822483
[No Abstract] [Full Text] [Related]
31. A brush with danger: historical review of topical immunotherapy for alopecia areata.
Macbeth AE; Lee KY; Levell NJ
Clin Exp Dermatol; 2013 Dec; 38(8):960-1. PubMed ID: 23795819
[No Abstract] [Full Text] [Related]
32. Treatment of alopecia areata in children.
Mukherjee N; Burkhart CN; Morrell DS
Pediatr Ann; 2009 Jul; 38(7):388-95. PubMed ID: 19685659
[No Abstract] [Full Text] [Related]
33. Squaric acid dibutylester treatment of alopecia areata.
Valsecchi R; Cainelli T; Tornaghi A; Rossi A; Perego GB; Smojver E; Panunzio M
Clin Exp Dermatol; 1985 May; 10(3):233-8. PubMed ID: 4006285
[No Abstract] [Full Text] [Related]
34. Contact urticaria during topical immunotherapy.
Tosti A; Guerra L; Bardazzi F
Contact Dermatitis; 1989 Sep; 21(3):196-7. PubMed ID: 2791547
[No Abstract] [Full Text] [Related]
35. Efficacy of topical sensitizers in the treatment of alopecia areata.
Rokhsar CK; Shupack JL; Vafai JJ; Washenik K
J Am Acad Dermatol; 1998 Nov; 39(5 Pt 1):751-61. PubMed ID: 9810892
[TBL] [Abstract][Full Text] [Related]
36. Treatment of alopecia areata with topical sensitizers.
Sutherland L; Laschinger M; Syed ZU; Gaspari A
Dermatitis; 2015; 26(1):26-31. PubMed ID: 25581667
[TBL] [Abstract][Full Text] [Related]
37. The pattern and profile of alopecia areata in Singapore--a study of 219 Asians.
Tan E; Tay YK; Goh CL; Chin Giam Y
Int J Dermatol; 2002 Nov; 41(11):748-53. PubMed ID: 12452996
[TBL] [Abstract][Full Text] [Related]
38. Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice.
Freyschmidt-Paul P; Sundberg JP; Happle R; McElwee KJ; Metz S; Boggess D; Hoffmann R
J Invest Dermatol; 1999 Jul; 113(1):61-8. PubMed ID: 10417620
[TBL] [Abstract][Full Text] [Related]
39. Role of topical immunotherapy in the treatment of alopecia areata. Quality analysis of articles published between January 1977 and January 1988 about three treatments. Reading Group.
Naldi L; Parazzini F; Cainelli T
J Am Acad Dermatol; 1990 Apr; 22(4):654-6. PubMed ID: 2138637
[TBL] [Abstract][Full Text] [Related]
40. Impaired responses of peripheral blood mononuclear cells to T-cell stimulants in alopecia areata patients with a poor response to topical immunotherapy.
Yoshino T; Asada H; Ando Y; Fujii H; Yamaguchi Y; Yoshikawa K; Itami S
Br J Dermatol; 2001 Sep; 145(3):415-21. PubMed ID: 11531830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
